National Centre for Epidemiology and Population Health, The Australian National University, Canberra, Australian Capital Territory, Australia.
Department of Medicine, Division of Neurology and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.
Mult Scler Relat Disord. 2022 Jul;63:103932. doi: 10.1016/j.msard.2022.103932. Epub 2022 May 29.
The incidence of multiple sclerosis (MS) has reportedly increased over time; however, change in MS incidence has not been rigorously assessed globally.
We followed the guidelines for the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Two independent reviewers systematically searched Scopus, PubMed and Web of Science for peer-reviewed publications in English from 1 January 1985 to 24 September 2020 reporting MS incidence for at least two contiguous five-year periods with clearly-defined case ascertainment. The outcome was change in MS incidence rate according to geographical region.
We identified 64 papers providing 65 regional estimates (including three paediatric-onset MS) across 24 countries covering ∼3% of the world's population (in 2000/1 or closest available total population for the entire country), with quality (adapted Newcastle-Ottawa Scale) ranging from sufficient to good. Studies were mainly from Italy (n=14 including San Marino), Norway (n=10) or Canada (n=9), with no studies in the Africa or South-East Asia regions. Of the 62 whole-of-population estimates, MS incidence rates: significantly increased in 38 (61%), significantly decreased in 13 (21%) and remained stable in 11 (18%). In the paediatric-onset studies, MS incidence was stable in two (67%) and increased in one (33%). Many estimates derived from only selected (often small) regions of a country. For 42 (68%) of the whole-of-population estimates (and two of the paediatric-onset estimates) a consistent case definition or diagnostic criteria over the entire study period was explicitly reported. Across the n=9 whole-of-population estimates based on a consistent case definition for the duration of the study period, and including a substantial proportion of the population of a country (≥one-third), incidence rates were stable in n=3, increased in n=3 and decreased in n=3. Studies using a consistent case definition covered ∼2.7% of the global population; incidence rates were stable in 0.9% of the global population, decreased in studies covering 1%, and increased in those covering 0.8% of the global population.
The studies reporting change in MS incidence rate over time were limited by world region and the proportion of the global population covered. Although by number of studies, the predominant pattern was increasing MS incidence, in studies where a consistent case definition was used across the duration of the study and with high population coverage, no predominant pattern of MS incidence was evident.
据报道,多发性硬化症(MS)的发病率随时间推移而增加;然而,全球尚未严格评估 MS 发病率的变化。
我们遵循了系统评价和荟萃分析的首选报告项目(PRISMA)声明的指南。两位独立的审查员系统地在 Scopus、PubMed 和 Web of Science 中搜索了从 1985 年 1 月 1 日至 2020 年 9 月 24 日发表的英文同行评审出版物,这些出版物报告了至少两个连续的五年期间的 MS 发病率,且具有明确的病例确定。结果是根据地理位置变化的 MS 发病率。
我们确定了 64 篇论文,提供了 24 个国家/地区的 65 个区域估计值(包括 3 个儿科发病 MS),涵盖了世界人口的约 3%(在 2000/1 年或整个国家/地区的可用总人口中最接近),质量(改编后的纽卡斯尔-渥太华量表)从充足到良好。研究主要来自意大利(n=14,包括圣马力诺)、挪威(n=10)或加拿大(n=9),非洲或东南亚地区没有研究。在 62 个全人群估计值中,MS 发病率:38 个(61%)显著增加,13 个(21%)显著降低,11 个(18%)保持稳定。在儿科发病研究中,2 个(67%)稳定,1 个(33%)增加。许多估计值仅来自一个国家的部分(通常较小)地区。对于 42 个(68%)全人群估计值(以及两个儿科发病估计值),在整个研究期间明确报告了一致的病例定义或诊断标准。在基于整个研究期间一致病例定义的 n=9 个全人群估计值中,包括一个国家的相当大比例(≥三分之一)的人口,发病率在 n=3 中稳定,在 n=3 中增加,在 n=3 中减少。使用一致病例定义的研究覆盖了全球人口的约 2.7%;在全球人口的 0.9%中发病率稳定,在覆盖 1%的研究中发病率降低,在覆盖全球人口 0.8%的研究中发病率增加。
随着时间的推移报告 MS 发病率变化的研究受到世界区域和全球人口覆盖比例的限制。尽管从研究数量来看,主要模式是 MS 发病率增加,但在整个研究期间使用一致病例定义且具有高人口覆盖率的研究中,MS 发病率没有明显的主要模式。